| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30011728 | HIV | ENSG00000139631.20 | protein_coding | CSAD | No | No | 51380 | Q86V02 Q9Y600 |
| TVIS30075213 | HIV | ENSG00000139631.20 | protein_coding | CSAD | No | No | 51380 | Q86V02 Q9Y600 |
| TVIS30032959 | HIV | ENSG00000139631.20 | protein_coding | CSAD | No | No | 51380 | Q86V02 Q9Y600 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CSAD |
|---|---|
| DrugBank ID | DB00151 |
| Drug Name | Cysteine |
| Target ID | BE0000079 |
| UniProt ID | Q9Y600 |
| Regulation Type | |
| PubMed IDs | 17139284; 17016423; 6953423; 236774; 7131091 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Chan-Palay V, Lin CT, Palay S, Yamamoto M, Wu JY: Taurine in the mammalian cerebellum: demonstration by autoradiography with [3H]taurine and immunocytochemistry with antibodies against the taurine-synthesizing enzyme, cysteine-sulfinic acid decarboxylase. Proc Natl Acad Sci U S A. 1982 Apr;79(8):2695-9.@@Guion-Rain M-C, Portemer C, Chatagner F: Rat liver cysteine sulfinate decarboxylase: purification, new appraisal of the molecular weight and determination of catalytic properties. Biochim Biophys Acta. 1975 Mar 28;384(1):265-76.@@Daniels KM, Stipanuk MH: The effect of dietary cysteine level on cysteine metabolism in rats. J Nutr. 1982 Nov;112(11):2130-41. |
| Groups | Approved; Nutraceutical |
| Direct Classification | Cysteine and derivatives |
| SMILES | N[C@@H](CS)C(O)=O |
| Pathways | Amiloride Action Pathway; gamma-Glutamyltranspeptidase Deficiency; 4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency; Hydroflumethiazide Action Pathway; Bumetanide Action Pathway; Polythiazide Action Pathway; Ethacrynic Acid Action Pathway; Cyclothiazide Action Pathway; Trichlormethiazide Action Pathway; gamma-Glutamyltransferase Deficiency; Methionine Adenosyltransferase Deficiency; Glutamate Metabolism; Chlorothiazide Action Pathway; Pantothenate and CoA Biosynthesis; Non-Ketotic Hyperglycinemia; 2-Hydroxyglutric Aciduria (D and L Form); Indapamide Action Pathway; Hyperinsulinism-Hyperammonemia Syndrome; Iminoglycinuria; Taurine and Hypotaurine Metabolism; Glycine and Serine Metabolism; Chlorthalidone Action Pathway; Bendroflumethiazide Action Pathway; Methionine Metabolism; Eplerenone Action Pathway; Cystathionine beta-Synthase Deficiency; Glucose Transporter Defect (SGLT2); Spironolactone Action Pathway; Sarcosinemia; Quinethazone Action Pathway |
| PharmGKB | PA449173 |
| ChEMBL | CHEMBL863 |
